Hyung Chun
Investing Profile
Foresite Capital thesis
"Foresite Capital has been a visionary partner." Serge Saxonov, CEO & Co-Founder 10x Genomics (See Disclosures) “Foresite Capital’s deep industry knowledge and in-house expertise has helped fuel our mission to outsmart cancer resistance.” Tim Clackson Theseus Pharmaceuticals (See Disclosures) "The Foresite team contributed meaningful scientific and strategic insights that supported our path from concept to acquisition in just over two years. Their partnership allowed our small team to move more quickly and decisively than we could have alone." Chris LeMasters XinThera (See Disclosures) "The Fo
Sector and stage focus
- Series A: BioTech
- Series B: BioTech
- general: Boston / New England
- Seed: BioTech
Recent investments by Hyung Chun
Hyung Chun has 2 named past investments in the public record. The most recent:
| Company | Stage | Date | Round size |
|---|---|---|---|
| Indomo | Seed | Oct 2025 | $25M |
| Latigo Biotherapeutics | Series B | Mar 2025 | $150M |
Is Hyung Chun a fit for your round?
Upload your pitch deck and see whether Hyung Chun appears in your top 20 matches.
Find investors for your deck